August 2021: The Food and Drug Administration has approved asparaginase erwinia chrysanthemi (recombinant)-rywn) (Rylaze, Jazz Pharmaceuticals, Inc.) as part of a multi-agent chemotherapeutic regimen for the treatment of acute lym..
August 2021: The FDA granted loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics SA), a CD19-directed antibody and alkylating agent conjugate, accelerated approval for adult patients with relapsed or refractory large B-cell ly..
August 2021: The FDA has given axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) expedited approval for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. A sing..
On June 17-20, 2015, the 13th International Lymphoma Conference was successfully held in Switzerland. 3700 representatives from 90 countries participated in the event. At the meeting, the research on lymphoma was brilliant, not o..
A review written by Young, MD, Anderson Cancer Center, USA explained the application of PD-1 inhibitor immunotherapy in B-cell lymphoma. (Blood. Online version on November 8, 2017. doi: 10.1182 / blood-2017-07-740993.)PD-1 immune..
The Cleveland Clinic of the United States Eric D. His et al. Reported that the diagnosis of peripheral T cell lymphoma (PTCL) in the United States varies greatly, and often lacks important phenotypic information to fully distingui..
Mature T-cell tumors, such as non-Hodgkin T-cell lymphoma, are highly invasive and drug-resistant, and patients often have a poor prognosis. Recently, "Nature" series of two articles published a new interpretation of the pathogene..
Obesity not only runs counter to the aesthetics of people, but also causes many chronic diseases. Some studies have shown that body mass index (BMI) is related to the risk of cancer in certain parts (such as the digestive system),..
Yesterday, the US FDA announced the approval of Seattle Genetics' antibody-drug conjugate Adcetris (brentuximab vedotin) in combination with chemotherapy for patients with previously treated stage III or IV classic Hodgkin's lymph..
New Cleveland Clinic research shows for the first time that FDA-approved ibrutinib (ibrutinib) for lymphoma and leukemia may also help treat the most common and deadly brain tumors, and may one day be used in patients with gliobla..